Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
5.62
-0.35 (-5.86%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Karyopharm Therapeutics Stock Forecast
KPTI's stock price has decreased by -65.63% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Karyopharm Therapeutics stock have an average target of 61, with a low estimate of 45 and a high estimate of 75. The average target predicts an increase of 985.41% from the current stock price of 5.62.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 3, 2025.
Analyst Ratings
The average analyst rating for Karyopharm Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $75 → $54 | Buy | Maintains | $75 → $54 | +860.85% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $56 | Strong Buy | Maintains | $7 → $56 | +896.44% | Feb 26, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $45 | Buy | Reiterates | $45 | +700.71% | Feb 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $105 | Strong Buy | Reiterates | $105 | +1,768.33% | Feb 20, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $45 | Buy | Reiterates | $45 | +700.71% | Feb 10, 2025 |
Financial Forecast
Revenue This Year
152.31M
from 145.24M
Increased by 4.87%
Revenue Next Year
177.12M
from 152.31M
Increased by 16.29%
EPS This Year
-14.63
from -14.00
EPS Next Year
-10.29
from -14.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 162.8M | 198.1M | 310.5M | ||
| Avg | 152.3M | 177.1M | 232.7M | ||
| Low | 141.5M | 151.9M | 189.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.1% | 30.1% | 75.3% | ||
| Avg | 4.9% | 16.3% | 31.4% | ||
| Low | -2.6% | -0.3% | 6.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -11.81 | -6.14 | -4.88 | ||
| Avg | -14.63 | -10.29 | -6.80 | ||
| Low | -16.41 | -18.38 | -8.92 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.